Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 1:35 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1489–1512 of 35,388 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: alone Clear all

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: COPD plus CAPTURE education and patient-level information, COPD Education Only; Other
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 45 Years to 80 Years
Enrollment: 2,004 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 9
States / cities: Los Angeles, California • Aurora, Colorado • Miami, Florida + 5 more

Conditions: Polycystic Ovary Syndrome, Hormone Imbalance
Interventions: Optify Myo Inositol and D-Chiro Inositol Plus Folate and Vitamin D supplement; Dietary Supplement
Lead sponsor: Optify; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Caloric Restriction, Exercise, Sleep
Interventions: Testosterone Undecanoate, Sesame Oil; Drug
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 18 Years to 35 Years · Male only
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Inflammatory Myelopathies
Interventions: FES Cycling, Cycling without FES, Lumbar puncture, Mood assessment; Device · Procedure · Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2019
U.S. locations: 1
States / cities: Lutherville, Maryland

Conditions: Iron Deficiency Anemia
Interventions: Ferric carboxymaltose; Drug
Lead sponsor: Sandoz; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Advanced Solid Tumors
Interventions: Nivolumab, Ipilimumab; Drug
Lead sponsor: Canadian Cancer Trials Group; Network
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Aqueous Deficient Dry Eye, Meibomium Gland Dysfunction
Interventions: Subjective Questionnaire, Measurement with wavefront sensor (right eye, then left eye), Instill Saline Drop; Behavioral · Procedure · Drug
Lead sponsor: University of Rochester; Other
Eligibility: 20 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Kidney Transplantation
Interventions: bleselumab, Placebo; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 21
States / cities: Palo Alto, California • San Diego, California • San Francisco, California + 16 more

Conditions: Malignant Neoplasms of Independent (Primary) Multiple Sites
Interventions: Questionnaires, Video Presentation; Behavioral · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Postoperative Cognitive Complications, Delirium, Perioperative/Postoperative Complications, Brain Injuries, Anesthesia
Interventions: Not listed
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Caregiver Burden, Alzheimer Disease
Interventions: Brain CareNotes, Dementia Guide Expert; Behavioral
Lead sponsor: Richard Holden; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Bloomington, Indiana

Conditions: Degenerative Mitral Valve Disease, Mitral Regurgitation, Mitral Insufficiency, Functional Mitral Regurgitation
Interventions: Edwards PASCAL System, Abbott Mitraclip System; Device
Lead sponsor: Edwards Lifesciences; Industry
Eligibility: 18 Years and older
Enrollment: 1,247 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2031
U.S. locations: 63
States / cities: Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 50 more

Conditions: Breast Cancer, Gynecologic Cancer
Interventions: prasterone, placebo; Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older · Female only
Enrollment: 464 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 280
States / cities: Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 185 more

Conditions: Rosacea, Papulopustular
Interventions: cold atmospheric plasma; Device
Lead sponsor: The Skin Center Dermatology Group; Industry
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: New City, New York

Conditions: Multiple Sclerosis
Interventions: transcranial direct current stimulation; Device
Lead sponsor: University of Iowa; Other
Eligibility: 18 Years to 70 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Myelofibrosis (MF)
Interventions: ABBV-744, Navitoclax, Ruxolitinib; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 10
States / cities: Sacramento, California • Lebanon, New Hampshire • Buffalo, New York + 6 more

Conditions: Hand Hygiene, Health Care Associated Infection, Compliance
Interventions: Hand Hygiene Signs; Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2019
U.S. locations: 10
States / cities: Miami, Florida • Iowa City, Iowa • Baltimore, Maryland + 7 more

Conditions: B-cell Childhood Acute Lymphoblastic Leukemia, Childhood Acute Lymphoblastic Leukemia in Remission, Recurrent Childhood Acute Lymphoblastic Leukemia
Interventions: laboratory biomarker analysis; Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: Not listed
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2012
U.S. locations: 1
States / cities: Monrovia, California

Conditions: Critical Limb Ischemia
Interventions: treprostinil dienthanolmine sustained release, Placebo; Drug
Lead sponsor: Ochsner Health System; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Melanoma (Skin)
Interventions: MART-1 antigen, gp100 antigen, incomplete Freund's adjuvant, recombinant interferon alfa, sargramostim, tyrosinase peptide; Biological
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 32
States / cities: Scottsdale, Arizona • Atlanta, Georgia • Decatur, Georgia + 24 more

Conditions: Hepatic Encephalopathy, Liver Failure, Hepatitis, Chronic, Liver Cirrhosis
Interventions: MARS, Standard Medical Therapy; Device · Drug
Lead sponsor: Vantive Health LLC; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2004
U.S. locations: 6
States / cities: Birmingham, Alabama • San Diego, California • Chicago, Illinois + 3 more

Conditions: Multiple Myeloma
Interventions: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Daratumumab, Lenalidomide, Pomalidomide, Dexamethasone; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 31
States / cities: Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 24 more

Conditions: Metastatic Pancreatic Adenocarcinoma
Interventions: metformin alone (Arm A), metformin (Arm B), rapamycin (Arm B); Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 2
States / cities: Scottsdale, Arizona • Baltimore, Maryland

Conditions: TQT Study
Interventions: Tetrodotoxin, Placebos; Drug
Lead sponsor: Wex Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Tempe, Arizona

Search by objective public record fields.

The CAPTURE Study: Validating a Unique COPD Case Finding Tool in Primary Care (Aim 3)

A Single Group Study to Evaluate the Effects of a Myo-Inositol and D-Chiro Inositol Supplement on Symptoms Associated With Polycystic Ovary Syndrome and Hormone Imbalance

Trial of Testosterone Undecanoate for Optimizing Performance During Military Operations

CNS Growth Factors Release and Changes in the Inflammatory Environment in Response to Electrical Stimulation in Subjects With Inflammatory Myelopathies

A Study Comparing Two Ferric Carboxymaltose Formulations in Patients With Iron Deficiency Anemia

Nivolumab Ipilimumab in Patients With hyperMutated Cancers Detected in Blood (NIMBLe)

Non-invasive Tear Film Dynamic Measurements in Normal, MGD and ADDE Subjects After Saline Instillation

A Study to Assess Pharmacokinetic, Pharmacodynamic, Safety and Tolerability of ASKP1240 in de Novo Kidney Transplantation

Communication Strategies to Introduce Psychology Services

Prospective Observational Multimodal Neuromonitoring During High-Risk Adult Surgery

I-CARE Rural Pilot: Intervention for Rural-Dwelling Dementia Caregivers

Edwards PASCAL CLASP IID/IIF Pivotal Clinical Trial

Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms

Rosacea Treatment Using Non-thermal (Cold) Atmospheric Plasma Device

tDCS to Lower Neuropathic Pain and Fatigue in People With Multiple Sclerosis

Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis

Building an Optimal Hand Hygiene Bundle

Studying Biomarkers as a Diagnostic Tool in Samples From Younger Patients With B-Cell Acute Lymphoblastic Leukemia

Safety Study of UT-15C SR (Oral Treprostinil) in Patients Undergoing a Lower Limb Endovascular Procedure

Vaccine Therapy With or Without Biological Therapy in Treating Patients With Metastatic Melanoma

Efficacy of Albumin Dialysis to Treat Patients With Hepatic Encephalopathy Using The Molecular Adsorbent Recirculating System (MARS)

A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)

A Study of Metformin With or Without Rapamycin as Maintenance Therapy After Induction Chemotherapy in Subjects With Pancreatic Cancer

A Phase 1, Single Ascending Dose, Randomized, Double-Blind, Placebo and Positive Controlled Study to Evaluate the Cardiovascular Effect of Tetrodotoxin in Healthy Adult Subjects